Wedbush Reiterates Neutral on Vera Therapeutics, Maintains $35 Price Target
Vera Therapeutics, Inc. Class A
Vera Therapeutics, Inc. Class A VERA | 0.00 |
Wedbush analyst Laura Chico reiterates Vera Therapeutics (NASDAQ:
VERA) with a Neutral and maintains $35 price target.
